01:32 AM EST, 11/10/2026 (MT Newswires) -- Valneva (VLA.PA) reported durable antibody persistence across all age groups from a single dose of its chikungunya vaccine, Ixchiq. The VLA1553-303 trial showed that 94% of the 221 healthy adults evaluable at year five maintained neutralizing antibody titers well above the seroresponse threshold, the Paris-listed specialty vaccine company said Tuesday. Adults aged 65 years and above demonstrated antibody persistence, which was comparable to the results in adults aged 18 to 64 years, with similar geometric mean titers and seroresponse rates. Valneva will continue to evaluate the participants and follow up for up to 10 years after vaccination.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.